Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. More Details
+ 1 more risk
Limited growth with imperfect balance sheet.
Share Price & News
How has Neovasc's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVCN's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NVCN underperformed the US Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: NVCN underperformed the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Neovasc's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall StDoes Neovasc Inc (NASDAQ:NVCN) Fall With The Market?
2 years ago | Simply Wall StWhat Do Analysts Think About Neovasc Inc's (NASDAQ:NVCN) Growth?
2 years ago | Simply Wall StNeovasc Inc (NASDAQ:NVCN): Is Breakeven Near?
Is Neovasc undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Neovasc is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Neovasc has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of NVCN's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore potentially undervalued companies in the Healthcare industry.
How is Neovasc forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVCN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVCN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVCN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVCN's revenue (155.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: NVCN's revenue (155.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NVCN's Return on Equity is forecast to be high in 3 years time
How has Neovasc performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVCN is currently unprofitable.
Growing Profit Margin: NVCN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVCN is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare NVCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVCN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: NVCN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Neovasc's financial position?
Financial Position Analysis
Short Term Liabilities: NVCN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NVCN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NVCN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NVCN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVCN has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: NVCN is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Neovasc current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NVCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVCN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVCN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVCN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fred Colen (67 yo)
Mr. Fredericus A. Colen, also known as Fred, has been President and Chief Executive Officer at Neovasc Inc. since January 22, 2018 and has been its Director since June 4, 2019. Mr. Colen has contributed to ...
CEO Compensation Analysis
Compensation vs Market: Fred's total compensation ($USD1.55M) is above average for companies of similar size in the US market ($USD606.89K).
Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.
|CFO & Corporate Secretary||13.42yrs||US$751.86k||0.0012% |
|Chief Operating Officer||0.83yr||US$2.48m||no data|
|Chief Quality Officer||0.33yr||US$399.56k||no data|
Experienced Management: NVCN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Independent Director||19.83yrs||US$102.85k||0.13% |
|Independent Director||15.25yrs||US$94.59k||0.067% |
|Independent Chairman of the Board||2.25yrs||US$102.85k||0.00091% |
|Independent Director||1yr||US$14.58k||0.15% |
Experienced Board: NVCN's board of directors are considered experienced (8.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 202.7%.
Neovasc Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neovasc Inc.
- Ticker: NVCN
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$63.185m
- Listing Market Cap: CA$47.117m
- Shares outstanding: 22.65m
- Website: https://www.neovasc.com
Number of Employees
- Neovasc Inc.
- 13562 Maycrest Way
- Suite 5138
- British Columbia
- V6V 2J7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVCN||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||May 2001|
|G5Z3||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||May 2001|
|NVCN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||May 2001|
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. Its products include ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 05:56|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.